Published 2017 | Version v1
Journal article

FDG PET-CT: Need for Vigilance in Patients Treated with Bleomycin

  • 1. Theagenion Cancer Hospital, Thessaloniki (Greece)
  • 2. Royal Free London NHS Foundation Trust, London (United Kingdom)
  • 3. KCL Division of Imaging Sciences & Biomedical Engineering, London (United Kingdom)

Description

Bleomycin-induced interstitial lung disease is not a rare complication of treatment and may prove to be fatal if not suspected early in its course. As FDG PET-CT has become an essential clinical tool for interim and end-of-treatment response assessment in oncology, it is important that radiologists/nuclear medicine specialists be aware of the features of this potentially treatable condition so that treatment can be instigated during an early reversible phase before pulmonary damage has occurred. Herein, we report two cases of bleomycin toxicity featuring different patterns on the treatment-response assessment FDG PET-CT scan.

Availability note (English)

Available from http://dx.doi.org/10.4103/0972-3919.202242; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439189

Additional details

Identifiers

Publishing Information

Journal Title
Indian Journal of Nuclear Medicine
Journal Volume
32
Journal Issue
2
Journal Page Range
p. 122-124
ISSN
0972-3919

INIS

Country of Publication
India
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
49087845
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BLEOMYCIN; NUCLEAR MEDICINE; POSITRON COMPUTED TOMOGRAPHY
Descriptors DEC
ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTIMITOTIC DRUGS; ANTINEOPLASTIC DRUGS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; MEDICINE; ORGANIC COMPOUNDS; TOMOGRAPHY

Optional Information

Notes
PMCID: PMC5439189; PMID: 28533640; PUBLISHER-ID: IJNM-32-122; OAI: oai:pubmedcentral.nih.gov:5439189; Copyright: (c) 2017 Indian Journal of Nuclear Medicine